NASDAQ : SUPN
Supernus Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 41.84 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.43B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.44B |
| Enterprise Value | 2.12B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 58.24M |
| Shares Outstanding | 58.24M |
| Shares Change (YoY) | +3.33% |
| Shares Change (QoQ) | +2.41% |
| Owned by Insiders (%) | 4.32% |
| Owned by Institutions (%) | 97.59% |
| Float | 51.85M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 10.98 |
| PS Ratio | 2.82 |
| Forward PS | 1.65 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 4.91 |
| P/FCF Ratio | 28.07 |
| P/OCF Ratio | 27.68 |
| PEG Ratio | 0.59 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.45 |
| EV / EBITDA | 18.25 |
| EV / EBIT | 136.57 |
| EV / FCF | 24.36 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.49 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 0.42 |
| Interest Coverage | 5.11 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -4.15% |
| Return on Assets (ROA) | 0.69% |
| Return on Invested Capital (ROIC) | 2.16% |
| Return on Capital Employed (ROCE) | 1.39% |
| Weighted Average Cost of Capital (WACC) | 7.29% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | -$56,370 |
| Employee Count | 778 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.76 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.05M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -24.71% |
| 50-Day Moving Average | 42.50 |
| 200-Day Moving Average | 47.29 |
| Relative Strength Index (RSI) | 50.99 |
| Average Volume (20 Days) | 1,153,548 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.04M |
| Short Previous Month | 4.99M |
| Short % of Shares Out | 6.94% |
| Short % of Float | 7.80% |
| Short Ratio (days to cover) | 5.36 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 865.11M |
| Gross Profit | 635.54M |
| Operating Income | 15.51M |
| Pretax Income | -42.80M |
| Net Income | -43.86M |
| EBITDA | 116.03M |
| EBIT | 15.51M |
| Loss Per Share | -$0.76 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 359.46M |
| Total Debt | 36.20M |
| Net Cash | 323.26M |
| Net Cash Per Share | $5.55 |
| Equity (Book Value) | 1.06B |
| Book Value Per Share | 18.24 |
| Working Capital | 425.82M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 88.18M |
| Capital Expenditures | -1.23M |
| Depreciation & Amortization | 100.52M |
| Net Borrowing | n/a |
| Free Cash Flow | 86.96M |
| FCF Per Share | $1.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | 73.46% |
| Operating Margin | 1.79% |
| Pretax Margin | -4.95% |
| Profit Margin | -5.07% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 1.79% |
| FCF Margin | 10.05% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.33% |
| Shareholder Yield | -3.33% |
| Earnings Yield | -1.82% |
| FCF Yield | 3.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $60.50 |
| Price Target Difference | 44.32% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 32.20% |
| EPS Growth Forecast (3Y) | 31.53% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 6.47 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |